Loading
NASDAQIndustrialsAerospace & Defense
Latest quote
$0.8408
−$0.0205 · -2.38%
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Previous close
$0.8408
−$0.0205 · -2.38%
Regular session · ET · Market data may be delayed.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Day range
Current $0.8408
52-week range
Current $0.8408
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
34
Expensive
Sentiment
52
Mixed
Risk
66
High Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Day range
Current $0.8408
52-week range
Current $0.8408
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 26.97K EUR | 46.51K EUR | 41.71K EUR | 6K EUR | 5.1K EUR |
| Gross profit | −26.97K EUR | −46.51K EUR | −41.71K EUR | −6K EUR | −5.1K EUR |
| Research and development | 2.59M EUR | 5.03M EUR | 6.36M EUR | 5.21M EUR | 3.53M EUR |
| Selling, general, and administrative | 3.72M EUR | 5.13M EUR | 5.12M EUR | 5.57M EUR | 2.39M EUR |
| Operating expenses | 6.32M EUR | 10.15M EUR | 11.48M EUR | 10.78M EUR | 5.92M EUR |
| Interest income | 968.7K EUR | — | — | — | — |
| Interest expense | 384.21K EUR | — | — | — | — |
| Depreciation and amortization | 26.97K EUR | 46.51K EUR | 41.71K EUR | 6K EUR | 5.1K EUR |
| Operating income | −6.34M EUR | −10.2M EUR | −11.53M EUR | −10.79M EUR | −5.93M EUR |
| Net income | −6.27M EUR | −9.31M EUR | −11.44M EUR | −8.28M EUR | −5.76M EUR |
Company facts updated Sep 13, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
